Publication

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

Journal Paper/Review - Jun 8, 2016

Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J